ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

Is Everyone in Academic Medicine Unhappy? Or is it Just MD Anderson?

December 12, 2014

DCE Board Demands Other Agencies Pay For NCI AIDS Support Contract, Okays Two RFA Concepts, One Program Announcement, Contract Recompetitions

May 24, 1985

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

September 30, 2011

Marvin Schneiderman To Retire March 1

February 8, 1980

Reports Propose Stricter Rules To Protect Research Participants

October 11, 2002

DCBD Board Rejects Breast Cancer Multiple Markers Concept Proposal

November 4, 1983